GSK prevails in Paxil suicide suit

Pre-emption handed GlaxoSmithKline the victory in a lawsuit over a 13-year-old who committed suicide while taking the antidepressant Paxil. A California judge cited the pre-emption rule in dismissing the suit, saying that the case created a direct conflict between federal labeling requirements and state tort law. Glaxo couldn't have complied with both, the judge said, and federal law pre-empts state law--so out with the suit.

The thing is, this ruling could not only set a precedent, causing all sorts of damage suits against drug companies to get tossed, but might be a harbinger of an even bigger precedent-setter. The Supreme Court is set to consider a couple of cases that rest on this notion of pre-emption. As the reasoning goes (greatly simplified; I'm no lawyer) the federal government vested FDA with the power to regulate drugs and devices, so FDA approval should shield drugs and devices from state liability.

- check out the coverage from Pharmalot

Related Articles:
UK patients sue for Paxil withdrawal. Report
Study highlights link between Paxil and suicide. Report
Glaxo to let Mylan make generic Paxil. Report
Study: Antidepressant warnings work. Report

Suggested Articles

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.

Pfizer's Upjohn has reached a deal to exclusively supply generic Viagra to telehealth provider Roman as the company prepares to merge with Mylan.